The jump from 1mg to 4mg produced nearly double the weight loss, from 8.7% to 17.1%, suggesting that the glucagon component only becomes meaningfully active somewhere in that dose range
They have not been formally established for retatrutide because retatrutide is not yet FDA approved, and clinical trial protocols handle missed doses through site-specific procedures rather than published guidance
This is significant because it suggests that lower maintenance doses may be sufficient for some populations, particularly those using retatrutide for conditions other than maximum weight loss
*Correspondence: Lamija Ferhatbegovi, [email protected] Disclaimer All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers
Human GLP-1 based GLP-1RA includes liraglutide, albiglutide, dulaglutide, efpeglenatide, and semaglutide
The flat pricing model, where your cost does not increase as your dose increases, is a legitimate advantage